News stories about PhaseRx (NASDAQ:PZRX) have trended somewhat positive this week, according to Accern Sentiment Analysis. The research firm rates the sentiment of media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. PhaseRx earned a news sentiment score of 0.09 on Accern’s scale. Accern also assigned headlines about the company an impact score of 44.4845280311967 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Shares of PhaseRx (PZRX) opened at $0.38 on Tuesday. The stock has a market capitalization of $4.44, a price-to-earnings ratio of -0.32 and a beta of 8.48. The company has a quick ratio of 2.14, a current ratio of 2.14 and a debt-to-equity ratio of -12.03. PhaseRx has a 52 week low of $0.36 and a 52 week high of $1.95.

PhaseRx (NASDAQ:PZRX) last announced its quarterly earnings data on Thursday, November 9th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.14.

Separately, Laidlaw cut PhaseRx from a “buy” rating to a “neutral” rating in a research note on Friday, October 13th.

TRADEMARK VIOLATION NOTICE: “PhaseRx (PZRX) Getting Somewhat Positive Media Coverage, Report Finds” was originally published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this story on another website, it was illegally copied and republished in violation of United States and international copyright laws. The correct version of this story can be viewed at

PhaseRx Company Profile

PhaseRx, Inc is a biopharmaceutical company developing a portfolio of mRNA products to correct life-threatening inherited liver diseases in children. The Company’s initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of 12 and are characterized by the body’s inability to remove ammonia from the blood.

Insider Buying and Selling by Quarter for PhaseRx (NASDAQ:PZRX)

Receive News & Ratings for PhaseRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PhaseRx and related companies with's FREE daily email newsletter.